<DOC>
	<DOCNO>NCT00765804</DOCNO>
	<brief_summary>The purpose study assess safety efficacy iontophoretic delivery dexamethasone phosphate ophthalmic solution use EyeGateÂ® II Drug Delivery System patient dry eye .</brief_summary>
	<brief_title>Safety Efficacy Study Iontophoresis Dexamethasone Phosphate Treat Dry Eye</brief_title>
	<detailed_description>The objective study assess safety efficacy Ocular Iontophoresis Dexamethasone Phosphate 40 mg/mL 7.5 mA-min 2.5 mA Ocular Iontophoresis Dexamethasone Phosphate 40 mg/mL 10.5 mA-min 3.5 mA compare placebo treatment sign symptom dry eye .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Have report history dry eye eye Be least 12 year age Demonstrate response expose Controlled Adverse Environment model Have contraindication use test article Have know allergy sensitivity study medication component ( include corticosteroid ) Have ocular infection , active ocular inflammation preauricular lymphadenopathy Be current contact lens wearer wear contact study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Dry Eye</keyword>
	<keyword>Iontophoresis</keyword>
	<keyword>Ophthalmic Delivery</keyword>
</DOC>